Abstract
These are exciting times for bioinformaticians, computational biologists and drug designers with the genome and proteome sequences and related structural databases growing at an accelerated pace. The post-genomic era has triggered high expectations for a rapid and successful treatment of diseases. However, in this biological information rich and functional knowledge poor scenario, the challenges are indeed grand, no less than the assembly of the genome of the whole organism. These include functional annotation of genes, identification of druggable targets, prediction of three-dimensional structures of protein targets from their amino acid sequences, arriving at lead compounds for these targets followed by a transition from bench to bedside. We propose here a “Genome to Hits In Silico” strategy (called Dhanvantari) and illustrate it on Chikungunya virus (CHIKV). “Genome to hits” is a novel pathway incorporating a series of steps such as gene prediction, protein tertiary structure determination, active site identification, hit molecule generation, docking and scoring of hits to arrive at lead compounds. The current state of the art for each of the steps in the pathway is high-lighted and the feasibility of creating an automated genome to hits assembly line is discussed.
Keywords: Genome annotation, protein folding, docking and scoring, lead molecule, CHIKV.
Current Pharmaceutical Design
Title:Genomes to Hits In Silico - A Country Path Today, A Highway Tomorrow: A Case Study of Chikungunya
Volume: 19 Issue: 26
Author(s): Anjali Soni, Khushhali M. Pandey, Pratima Ray and B. Jayaram
Affiliation:
Keywords: Genome annotation, protein folding, docking and scoring, lead molecule, CHIKV.
Abstract: These are exciting times for bioinformaticians, computational biologists and drug designers with the genome and proteome sequences and related structural databases growing at an accelerated pace. The post-genomic era has triggered high expectations for a rapid and successful treatment of diseases. However, in this biological information rich and functional knowledge poor scenario, the challenges are indeed grand, no less than the assembly of the genome of the whole organism. These include functional annotation of genes, identification of druggable targets, prediction of three-dimensional structures of protein targets from their amino acid sequences, arriving at lead compounds for these targets followed by a transition from bench to bedside. We propose here a “Genome to Hits In Silico” strategy (called Dhanvantari) and illustrate it on Chikungunya virus (CHIKV). “Genome to hits” is a novel pathway incorporating a series of steps such as gene prediction, protein tertiary structure determination, active site identification, hit molecule generation, docking and scoring of hits to arrive at lead compounds. The current state of the art for each of the steps in the pathway is high-lighted and the feasibility of creating an automated genome to hits assembly line is discussed.
Export Options
About this article
Cite this article as:
Soni Anjali, Pandey M. Khushhali, Ray Pratima and Jayaram B., Genomes to Hits In Silico - A Country Path Today, A Highway Tomorrow: A Case Study of Chikungunya, Current Pharmaceutical Design 2013; 19 (26) . https://dx.doi.org/10.2174/13816128113199990379
DOI https://dx.doi.org/10.2174/13816128113199990379 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exogenous Expression of WNT7A in Leukemia-Derived Cell Lines Induces Resistance to Chemotherapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry Gene and process level modulation to overcome the bottlenecks of recombinant proteins expression in Pichia pastoris
Current Pharmaceutical Biotechnology Role of Pharmacogenomics in Antiepileptic Drug Therapy: Current Status and Future Perspectives
Current Pharmaceutical Design ABC Transporters in the CNS – An Inventory
Current Pharmaceutical Biotechnology How Much is Enough? Modulation of Dose-Response Curve for Steroid Receptor-Regulated Gene Expression by Changing Concentrations of Transcription Factor
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Drugs and Pregnancy (Guest Editor: Zaneta Kimber-Trojnar)]
Current Pharmaceutical Biotechnology Expansion or Depletion of T Follicular Helper Cells During HIV Infection: Consequences for B cell Responses
Current HIV Research Common Features of the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease
Reviews on Recent Clinical Trials Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Influence of Quaternary Conformation on the Biological Activities of the Asp49-phospholipases A2s from Snake Venoms
Protein & Peptide Letters A Novel Assay Platform for the Detection of Translation Modulators of Spermidine/ Spermine Acetyltransferase
Current Pharmaceutical Design Cystoid Macular Edema Due to Accidental Latanoprost Overdose After Uncomplicated Phacoemulsification
Current Drug Safety Promising Targets for Anti-Hepatitis C Virus Agents
Current Medicinal Chemistry Meet Our Editorial Board Member:
Current Pharmaceutical Biotechnology Antiviral Activity and Molecular Targets of Plant Natural Products Against Avian Influenza Virus
Current Organic Chemistry Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present)
Recent Patents on Anti-Cancer Drug Discovery Potential of Selected Indian Herbs for COVID-19
Current Traditional Medicine Pro-inflammatory Cytokines Modulate Glial Apolipoprotein E Secretion
Current Alzheimer Research Serum Proteome Profiling to Identify Proteins Promoting Pathogenesis of Non-atopic Asthma
Protein & Peptide Letters Positron Emitting Tracers in Pre-Clinical Drug Development
Current Radiopharmaceuticals